ON POISONS AND DISEASE AND SOME EXPERIMENTS WITH THE TOXIN OF THE BACILLUS TETANI.

J. J. Abel

DOI: https://doi.org/10.1126/SCIENCE.79.2041.121

IF: 56.9

1934-02-09

Science

Abstract:

What problem does this paper attempt to address?

Power-assisted liposuction (PAL) of multiple symmetric lipomatosis (MSL)--a longitudinal study

Mathias Tremp,Reto Wettstein,Laurent A Tchang,Dirk J Schaefer,Ulrich M Rieger,Daniel F Kalbermatten

DOI: https://doi.org/10.1016/j.soard.2014.05.004

Abstract:Background: Multiple symmetric lipomatosis (MSL) is a rare condition leading to grotesque disfigurement. Complete removal is almost impossible and recurrences inevitable. The objective of this study was to evaluate powered-assisted liposuction (PAL) for the treatment of MSL. Methods: Magnetic resonance imaging (MRI) was performed before and after surgery for quality assessment. To exclude malignancy incisional biopsies were taken before surgery. Outcome measures included aspiration volumes, duration of surgery, early morbidity, recurrence rates, and overall patient satisfaction. Results: Seven male patients aged between 43 and 70 years were identified. The mean liposuction volume equaled 2948±1566 mL, the mean surgery time 74±28 minutes. One hematoma was observed, whereas 1 recurrence rate was noticed after a mean follow-up of 14 months. Malignancy was excluded by histology in 5 patients. Preoperative MRI confirmed the diagnosis with no signs for malignancy and showed an efficient removal of the lesions. After a mean follow-up of 18 months, a high patient satisfaction was achieved. Conclusion: PAL can serve as an efficient method for the treatment of MSL. It has a significant effect on tightening of the skin, leading to a high patient satisfaction.
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

Tatjana Radosavljevic,Milica Brankovic,Janko Samardzic,Jasmina Djuretić,Dusan Vukicevic,Danijela Vucevic,Vladimir Jakovljevic

DOI: https://doi.org/10.3390/antiox13080906

IF: 7.675

2024-07-27

Antioxidants

Abstract:Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a range of liver conditions from steatosis to nonalcoholic steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis of MASLD involves metabolic dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role of mitochondrial dysfunction in MASLD's progression. Therapeutically, enhancing mitochondrial function has gained interest, along with lifestyle changes and pharmacological interventions targeting mitochondrial processes. The FDA's approval of resmetirom for metabolic-associated steatohepatitis (MASH) with fibrosis marks a significant step. While resmetirom represents progress, further research is essential to understand MASLD-related mitochondrial dysfunction fully. Innovative strategies like gene editing and small-molecule modulators, alongside lifestyle interventions, can potentially improve MASLD treatment. Drug repurposing and new targets will advance MASLD therapy, addressing its increasing global burden. Therefore, this review aims to provide a better understanding of the role of mitochondrial dysfunction in MASLD and identify more effective preventive and treatment strategies.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Integrated proteomic and metabolomic analyses of the mitochondrial neurodegenerative disease MELAS

Haorong Li,Martine Uittenbogaard,Ryan Navarro,Mustafa Ahmed,Andrea Gropman,Anne Chiaramello,Ling Hao

DOI: https://doi.org/10.1039/d1mo00416f

2022-03-28

Abstract:MELAS (mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes) is a progressive neurodegenerative disease caused by pathogenic mitochondrial DNA variants. The pathogenic mechanism of MELAS remains enigmatic due to the exceptional clinical heterogeneity and the obscure genotype-phenotype correlation among MELAS patients. To gain insights into the pathogenic signature of MELAS, we designed a comprehensive strategy integrating proteomics and metabolomics in patient-derived dermal fibroblasts harboring the ultra-rare MELAS pathogenic variant m.14453G>A, specifically affecting the mitochondrial respiratory complex I. Global proteomics was achieved by data-dependent acquisition (DDA) and verified by data-independent acquisition (DIA) using both Spectronaut and the recently launched MaxDIA platforms. Comprehensive metabolite coverage was achieved for both polar and nonpolar metabolites in both reverse phase and HILIC LC-MS/MS analyses. Our proof-of-principle MELAS study with multi-omics integration revealed OXPHOS dysregulation with a predominant deficiency of complex I subunits, as well as alterations in key bioenergetic pathways, glycolysis, tricarboxylic acid cycle, and fatty acid β-oxidation. The most clinically relevant discovery is the downregulation of the arginine biosynthesis pathway, likely due to blocked argininosuccinate synthase, which is congruent with the MELAS cardinal symptom of stroke-like episodes and its current treatment by arginine infusion. In conclusion, we demonstrated an integrated proteomic and metabolomic strategy for patient-derived fibroblasts, which has great clinical potential to discover therapeutic targets and design personalized interventions after validation with a larger patient cohort in the future.
A Mediterranean Diet-Oriented Intervention Rescues Impaired Blood Cell Bioenergetics in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Agnese Segala,Marika Vezzoli,Alice Vetturi,Emirena Garrafa,Barbara Zanini,Emanuela Bottani,Monica Marullo,Silvia Marconi,Chiara Ricci,Alessandra Valerio

DOI: https://doi.org/10.3390/diagnostics14182041

IF: 3.6

2024-09-15

Diagnostics

Abstract:Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a novel term for Non-Alcoholic Fatty Liver Disease (NAFLD), is associated with liver mitochondrial dysfunction. We previously demonstrated that mitochondrial respiratory capacity in peripheral blood mononuclear cells (PBMCs) was significantly reduced in patients with MASLD compared to non-MASLD controls. For MASLD treatment, guidelines recommend behavioral and dietary changes to reduce body weight. A recent 12-month clinical trial demonstrated that ameliorating patients' lifestyles through improved adherence to the Mediterranean diet and encouraged physical activity results in MASLD remission or regression. Methods: As a sub-study of the 12-month clinical trial, we evaluated the effects of the Mediterranean diet-oriented intervention on PBMC mitochondrial DNA content and respiratory parameters and on various biomarkers associated with MASLD. Results: Contrary to what was found at the baseline, after twelve months of intervention, systemic inflammatory and bioenergetics parameters did not differ between MASLD patients (N = 15) and control subjects (N = 17). PBMCs from MASLD subjects showed rescued basal respiration, ATP-linked respiration, maximal respiration, and spare respiratory capacity. The observed recovery coincided with a significant increase in the patients' adherence to the Mediterranean diet (Medscore). Conclusions: Our findings indicate that a Mediterranean diet-oriented intervention, without calorie reduction, preserves blood cell mitochondrial function in MASLD subjects. Thus, PBMC bioenergetics-based assays might be taken into account not only for diagnosing but also for monitoring therapeutic responses in MASLD.

medicine, general & internal
Mitophagy modulation rescues single large-scale mitochondrial DNA deletion (SLSMD) disease symptoms in the C. elegans uaDf5 animal model.

Ryan M Mendel,Sofie Matsuno,Alex Lu,Marni J Falk,Suraiya Haroon

DOI: https://doi.org/10.1101/2024.10.27.620333

2024-10-27

Abstract:Single large scale mitochondrial DNA (mtDNA) deletions (SLSMD) underlie a range of sporadic or maternally inherited primary mitochondrial diseases having significant morbidity and mortality, including Pearson syndrome, Kearns-Sayre Syndrome, or Chronic Progressive External Ophthalmoplegia. Therapeutic development has been hindered by limited existing knowledge on mtDNA quality control and a lack of SLSMD animal models. To address this challenge, we utilized the C. elegans heteroplasmic SLSMD strain, uaDf5, to objectively screen for potential therapies. As mitophagy modulation has been implicated in mtDNA homeostasis, we screened a library of mitophagy modulating compounds to determine their comparative effects to rescue mitochondrial unfolded protein (UPRmt) stress induction in in uaDf5 SLSMD worms. Interestingly, Thiamine was discovered to be an effective positive control, significantly reducing mitochondrial stress in this model. Two lead therapeutic candidates from the mitophagy library screen were Hemin and Celastrol (Tripterin). Celastrol is a mitophagy activating anti-inflammatory and metabolic modifying natural product derived compound, that rescued multiple fitness outcomes (thrashing, development, survival) and reduced the mitochondrial stress in uaDf5 animals in a mitophagy-dependent fashion. This study highlights the utility of the uaDf5 worm model to enable preclinical identification of therapeutic candidate leads for SLSMD-based heteroplasmic mtDNA diseases and identifies possible therapeutic candidates that serve as mitophagy modulators to improve health and specifically reduce heteroplasmy levels in SLSMD diseases.

Cell Biology
AI-based Digital Pathology Provides Newer Insights into Lifestyle Intervention-Induced Fibrosis Regression in MASLD: an Exploratory Study.

Hai-Yang Yuan,Xiao-Fei Tong,Ya-Yun Ren,Yang-Yang Li,Xin-Lei Wang,Li-Li Chen,Sui-Dan Chen,Xiao-Zhi Jin,Xiao-Dong Wang,Giovanni Targher,Christopher D. Byrne,Lai Wei,Vincent W-S Wong,Dean Tai,Arun J. Sanyal,Hong You,Ming-Hua Zheng

DOI: https://doi.org/10.1111/liv.16025

IF: 8.754

2024-01-01

Liver International

Abstract:Background and Aims: Lifestyle intervention is the mainstay of therapy for metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis is a key consequence of MASH that predicts adverse clinical outcomes. The placebo response plays a pivotal role in the outcome of MASH clinical trials. Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence analyses can provide an automated quantitative assessment of fibrosis features on a continuous scale called qFibrosis. In this exploratory study, we used this approach to gain insight into the effect of lifestyle intervention-induced fibrosis changes in MASH. Methods: We examined unstained sections from paired liver biopsies (baseline and end-of-intervention) from MASH individuals who had received either routine lifestyle intervention (RLI) (n = 35) or strengthened lifestyle intervention (SLI) (n = 17). We quantified liver fibrosis with qFibrosis in the portal tract, periportal, transitional, pericentral, and central vein regions. Results: About 20% (7/35) and 65% (11/17) of patients had fibrosis regression in the RLI and SLI groups, respectively. Liver fibrosis tended towards no change or regression after each lifestyle intervention, and this phenomenon was more prominent in the SLI group. SLI-induced liver fibrosis regression was concentrated in the periportal region. Conclusion: Using digital pathology, we could detect a more pronounced fibrosis regression with SLI, mainly in the periportal region. With changes in fibrosis area in the periportal region, we could differentiate RLI and SLI patients in the placebo group in the MASH clinical trial. Digital pathology provides new insight into lifestyle-induced fibrosis regression and placebo responses, which is not captured by conventional histological staging.
Metabolic effects of bezafibrate in mitochondrial disease

Hannah Steele,Aurora Gomez‐Duran,Angela Pyle,Sila Hopton,Jane Newman,Renae J Stefanetti,Sarah J Charman,Jehill D Parikh,Langping He,Carlo Viscomi,Djordje G Jakovljevic,Kieren G Hollingsworth,Alan J Robinson,Robert W Taylor,Leonardo Bottolo,Rita Horvath,Patrick F Chinnery

DOI: https://doi.org/10.15252/emmm.201911589

2020-02-28

EMBO Molecular Medicine

Abstract:<p>Mitochondrial disorders affect 1/5,000 and have no cure. Inducing mitochondrial biogenesis with bezafibrate improves mitochondrial function in animal models, but there are no comparable human studies. We performed an open‐label observational experimental medicine study of six patients with mitochondrial myopathy caused by the m.3243A>G <i>MTTL1</i> mutation. Our primary aim was to determine the effects of bezafibrate on mitochondrial metabolism, whilst providing preliminary evidence of safety and efficacy using biomarkers. The participants received 600–1,200 mg bezafibrate daily for 12 weeks. There were no clinically significant adverse events, and liver function was not affected. We detected a reduction in the number of complex IV‐immunodeficient muscle fibres and improved cardiac function. However, this was accompanied by an increase in serum biomarkers of mitochondrial disease, including fibroblast growth factor 21 (FGF‐21), growth and differentiation factor 15 (GDF‐15), plus dysregulation of fatty acid and amino acid metabolism. Thus, although potentially beneficial in short term, inducing mitochondrial biogenesis with bezafibrate altered the metabolomic signature of mitochondrial disease, raising concerns about long‐term sequelae.</p>

medicine, research & experimental
Copyright enforcement in the digital age: a post-ACTA view on the balancing of fundamental rights

I. Baraliuc,Sari Depreeuw,S. Gutwirth

DOI: https://doi.org/10.1093/ijlit/eas024

2013-03-01

International Journal of Law and Information Technology

Abstract:The ratification process of the Anti-Counterfeiting Trade Agreement (ACTA) in the European Union has raised many (academic and non-academic) questions on various aspects of the enforcement of intellectual property rights (IPR), one of them being the relation between copyright enforcement and the fundamental rights of (alleged) infringers. In this article, we analyse this relation in the context of the existing European framework, with particular attention for the pertinent decisions of the Court of Justice of the European Union (CJEU). We then assess whether the measures proposed in ACTA upset the balance set by the CJEU. While the rejection of ACTA by the European Parliament seems to relieve the most imminent threats, the review of the IPR Enforcement directive and *A first and significantly shorter version of this article, has already been published: Irina Baraliuc, Sari Depreeuw and Serge Gutwirth, ‘Copyright Enforcement in Europe after ACTA: What Now?’ (2012) 2 Netherlands J Legal Philos 99–104. Doctoral researcher at the Research Group Law, Science, Technology & Society (LSTS) at the Vrije Universiteit Brussel, Pleinlaan 2 (Room 4B306), 1050, Brussels, Belgium. Telephone: þ32 2 629 1194; Fax: þ32 2 629 2662; E-mail: irina.baraliuc@vub.ac.be. zPost-doc researcher at the Research Group Law, Science, Technology & Society (LSTS) at the Vrije Universiteit Brussel and attorney-at-law at the Brussels bar, Pleinlaan 2 (Room 4B304), 1050, Brussels, Belgium. Telephone: þ32 2 629 1586; Fax: þ32 2 629 2662; E-mail: sari.depreeuw@vub.ac.be. **Professor at the Faculty of Law and Criminology of the Vrije Universiteit Brussel and director of the Research Group Law, Science, Technology & Society (LSTS), Pleinlaan 2 (Room 4B317), 1050, Brussels, Belgium. Telephone: þ32 2 629 2642; Fax: þ32 2 629 2662; E-mail: serge.gutwirth@vub.ac.be. 92 at C aeton U niersity on Jne 3, 2015 http://ijlirdjournals.org/ D ow nladed from other Commission initiatives, including bilateral agreements, should keep the discussion alive.
Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?

Guillaume Henin,Audrey Loumaye,Louise Deldicque,Isabelle A. Leclercq,Nicolas Lanthier

DOI: https://doi.org/10.1111/liv.15938

IF: 8.754

2024-04-18

Liver International

Abstract:Myosteatosis is highly prevalent in metabolic dysfunction‐associated steatotic liver disease (MASLD) and could reciprocally impact liver function. Decreasing muscle fat could be indirectly hepatoprotective in MASLD. We conducted a review to identify interventions reducing myosteatosis and their impact on liver function. Non‐pharmacological interventions included diet (caloric restriction or lipid enrichment), bariatric surgery and physical activity. Caloric restriction in humans achieving a mean weight loss of 3% only reduces muscle fat. Lipid‐enriched diet increases liver fat in human with no impact on muscle fat, except sphingomyelin‐enriched diet which reduces both lipid contents exclusively in pre‐clinical studies. Bariatric surgery, hybrid training (resistance exercise and electric stimulation) or whole‐body vibration in human decrease both liver and muscle fat. Physical activity impacts both phenotypes by reducing local and systemic inflammation, enhancing insulin sensitivity and modulating the expression of key mediators of the muscle‐liver‐adipose tissue axis. The combination of diet and physical activity acts synergistically in liver, muscle and white adipose tissue, and further decrease muscle and liver fat. Several pharmacological interventions (patchouli alcohol, KBP‐089, 2,4‐dinitrophenol methyl ether, adipoRon and atglistatin) and food supplementation (vitamin D or resveratrol) improve liver and muscle phenotypes in pre‐clinical studies by increasing fatty acid oxidation and anti‐inflammatory properties. These interventions are effective in reducing myosteatosis in MASLD while addressing the liver disease itself. This review supports that disturbances in inter‐organ crosstalk are key pathophysiological mechanisms involved in MASLD and myosteatosis pathogenesis. Focusing on the skeletal muscle might offer new therapeutic strategies to treat MASLD by modulating the interactions between liver and muscles.

gastroenterology & hepatology
Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes

Elad Jacoby,Omer Bar-Yosef,Noah Gruber,Einat Lahav,Nira Varda-Bloom,Yoav Bolkier,Diana Bar,Moriya Ben-Yakir Blumkin,Sharon Barak,Etzyona Eisenstein,Jaana Ahonniska-Assa,Tamar Silberg,Tal Krasovsky,Orly Bar,Neta Erez,Bella Bielorai,Hana Golan,Benjamin Dekel,Michal J Besser,Gat Pozner,Hanan Khoury,Alan Jacobs,John Campbell,Eli Herskovitz,Noa Sher,Natalie Yivgi-Ohana,Yair Anikster,Amos Toren

DOI: https://doi.org/10.1126/scitranslmed.abo3724

2022-12-21

Abstract:Patients with single large-scale mitochondrial DNA (mtDNA) deletion syndromes (SLSMDs) usually present with multisystemic disease, either as Pearson syndrome in early childhood or as Kearns-Sayre syndrome later in life. No disease-modifying therapies exist for SLSMDs. We have developed a method to enrich hematopoietic cells with exogenous mitochondria, and we treated six patients with SLSMDs through a compassionate use program. Autologous CD34+ hematopoietic cells were augmented with maternally derived healthy mitochondria, a technology termed mitochondrial augmentation therapy (MAT). All patients had substantial multisystemic disease involvement at baseline, including neurologic, endocrine, or renal impairment. We first assessed safety, finding that the procedure was well tolerated and that all study-related severe adverse events were either leukapheresis-related or related to the baseline disorder. After MAT, heteroplasmy decreased in the peripheral blood in four of the six patients. An increase in mtDNA content of peripheral blood cells was measured in all six patients 6 to 12 months after MAT as compared baseline. We noted some clinical improvement in aerobic function, measured in patients 2 and 3 by sit-to-stand or 6-min walk testing, and an increase in the body weight of five of the six patients suffering from very low body weight before treatment. Quality-of-life measurements as per caregiver assessment and physical examination showed improvement in some parameters. Together, this work lays the ground for clinical trials of MAT for the treatment of patients with mtDNA disorders.
Surgical animal model of ventricular hypertrophy.

G. Marano,A. Ferrari

DOI: https://doi.org/10.1007/978-1-59745-571-8_5

Abstract:
Repeated measurements and data integration to monitor and study MASLD patients experiencing weight loss

P. Torre,L. Schiavo,B.M. Motta,M. Aquino,F. Belladonna,M. Masarone,M. Persico

DOI: https://doi.org/10.1016/j.dld.2024.01.093

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction MASLD is a multifactorial disease for which there are no approved pharmacological therapies and for which lifestyle changes still represent the most effective remedy. Nutritional studies could be essential to increase knowledge and assess causality in the field of MASLD. Aim Our aim is to monitor patients diagnosed with MASLD who attend a weight-loss program at our Hepatology Unit, through repeated measurements of clinical parameters, transient elastography (TE), controlled attenuation parameter (CAP), and blood tests. The interaction between genetics and TE/CAP is also considered. Patients and Methods Overweight or obese MASLD patients, aged ≥ 18, without decompensated cirrhosis or active cancer, were proposed to start a low-glycemic index, nutritionist-guided diet. Weight, BMI, TE/CAP, and blood tests recorded at baseline were compared with the same measurements obtained after 6 months. Weight loss was categorized into classes of weight change compared to baseline (<5%, 5%–10%, >10%). A genetic risk score (GRS) was calculated for each patient and related to changes in TE/CAP Results Among the 131 patients who underwent the first nutritional visit, 50 attended the 6-months control visit to date. At this time-point, as we previously observed in earlier follow-up visits, a significant difference compared to baseline was found in weight, BMI, and CAP (respectively -7.47 kg [-8.10%], -2.67 Kg/m2, and -45.88 dB/m; all p<0.0001). The latter improved proportionally to the extent of weight loss; mean liver stiffness, on the contrary, remained almost unchanged, but it decreased in the >10% weight reduction class. Patients with high GRS experienced a greater decrease in TE/CAP values after 6 months of diet. Liver biochemistry also improved. Conclusions Diet-induced weight loss has beneficial effects on MASLD, and liver disease improves proportionally to its extent. Genetics appear to modulate change in liver disease severity in patients on diet. Weight loss data represent the backbone of our ongoing studies on changes in metabolomics and gut microbiota for these patients, aimed at further investigate the pathophysiology of the disease.

gastroenterology & hepatology
1 nJ all-fiber 108 MHz mode-locked erbium oscillator at 1.56 /spl mu/m

A. Ruhl,M. Engelbrecht,H. Hundertmark,P. Wessels,D. Wandt,C. Fallnich

DOI: https://doi.org/10.1109/CLEO.2005.202148

2005-05-22

Abstract:We report on an all-fiber passively-mode-locked erbium ring oscillator with an output power of 103 mW. The diode-pumped oscillator's repetition rate was about 108 MHz resulting in a pulse energy of about 1 nJ.
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment

Takashi Tsuchiya,So Yeon Kim,Michitaka Matsuda,Jieun Kim,Alexsandr Stotland,Mitsuru Naiki,Ekihiro Seki

DOI: https://doi.org/10.1097/hc9.0000000000000480

2024-07-18

Hepatology Communications

Abstract:Background: The prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) has increased in recent decades. Approximately 25% of patients with MASLD progress to metabolic dysfunction–associated steatohepatitis, which is characterized by hepatic steatosis plus hepatocyte damage, inflammation, and fibrosis. We previously reported that Neurotropin (NTP), a drug used for relieving pain in Japan and China, inhibits lipid accumulation in hepatocytes by preventing mitochondrial dysfunction. We hypothesized that inhibiting hepatic steatosis and inflammation by NTP can be an effective strategy for treating MASLD and tested this hypothesis in a MASLD mouse model. Methods: Six-week-old C57BL/6NJ male mice were fed a normal diet and normal drinking water or a high-fat diet with high fructose/glucose water for 12 weeks. During the last 6 weeks, the mice were also given high-dose NTP, low-dose NTP, or control treatment. Histologic, biochemical, and functional tests were conducted. MitoPlex, a new proteomic platform, was used to measure mitochondrial proteins, as mitochondrial dysfunction was previously reported to be associated with MASLD progression. Results: NTP inhibited the development of hepatic steatosis, injury, inflammation, and fibrosis induced by feeding a high-fat diet plus high fructose/glucose in drinking water. NTP also inhibited HSC activation. MitoPlex analysis revealed that NTP upregulated the expression of mitochondrial proteins related to oxidative phosphorylation, the tricarboxylic acid cycle, mitochondrial dynamics, and fatty acid transport. Conclusions: Our results indicate that NTP prevents the development of hepatic steatosis, injury, and inflammation by preserving mitochondrial function in the liver and inhibits liver fibrosis by suppressing HSC activation. Thus, repurposing NTP may be a beneficial option for treating MASLD/metabolic dysfunction–associated steatohepatitis.

gastroenterology & hepatology
Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals

E. Paolini,M. Longo,M. Meroni,P. Podini,A. Quattrini,A.L. Fracanzani,P. Dongiovanni

DOI: https://doi.org/10.1016/j.dld.2024.01.017

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Introduction Mitochondrial dysfunction is a key player in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) onset and progression. The co-presence of loss-of-function mutations in PNPLA3, TM6SF2 and MBOAT7 genes impacts on mitochondrial morphology and function in in vitro models. Conversely, the restore of MBOAT7 and/or TM6SF2 activity in knock-out HepG2 cells decreased the number of misshapen-dysfunctional mitochondria and improved OXPHOS capacity. Aims To translate our in vitro findings into a clinical perspective and discover novel non-invasive biomarkers, we assessed mitochondrial activity in 41 MASLD patients stratified according to GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 genotype, of whom frozen liver biopsies and peripheral blood mononuclear cells (PBMCs) were available. Method H2O2, ROS, mitochondrial complexes activities were measured by enzymatic assays, the oxygen consumption rate (OCR) by Seahorse. Results According to our in vitro results, liver biopsies and PBMCs of GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 carriers, alone and especially combined (number of risk variants, NRV=3), showed higher H2O2 and ROS than MASLD patients with no variants. Consistently, the activity of mitochondrial complexes I, III, citrate and ATP synthase was lower in biopsies and PBMCs of GG-PNPLA3, TT-MBOAT7 and TT-TM6SF2 individuals, showing the sharpest effect in their co-presence (*p<0.05, **p<0.001, ***p<0.0001 vs NRV=0). Finally, biopsies and PBMCs of NRV=3 subjects exhibited OCR depletion yielded by complex I/IV and II/IV activities compared to NRV=0 at Seahorse (***p<0.0001). At multivariate analysis adjusted for age, gender, BMI, diabetes and MASLD severity, NRV=3 was associated with reduced OCR in hepatic biopsies (β=-21.24) and PBMCs (β=-20.08) (p<0.0001). Finally, at nominal logistic analysis, adjusted for NRV=3, OCR predicted MASH-fibrosis with AUC of 0.81 and 0.86 in biopsies and PBMCs, respectively. Conclusion PBMCs mitochondrial activity is impaired in NRV=3 carriers and completely reflects the hepatic one. Therefore, PBMCs bioenergetic profile could represent a potential non-invasive biomarker of disease severity in MASLD genetically predisposed individuals.

gastroenterology & hepatology
Duodenal and jejunal diverticula causing a pneumoperitoneum.

M. Madura,R. Craig

DOI: https://doi.org/10.1097/00004836-198100031-00013

Journal of Clinical Gastroenterology

Abstract:ABSTRACT A 73-year-old man had vague, mild epigastric discomfort and was subsequently noted to have a nonsurgical pneumoperitoneum, probably from duodenal and jejunal diverticulosis. We suggest a similarity between the formation of gas-filled cysts in pneumatosis cystoides intestinalis and the pneumoperitoneum with jejunal diverticulosis. Bacterial gas production may have an important etiologic role.
[Evaluation for submental island flap].

Yue-huang Wu,P. Tang,Y. Qi,Zhengang Xu,Yongdong He

2002-11-01

Abstract:OBJECTIVE To evaluate the clinical effect of submental island flap. METHODS The influence of head and neck radiotherapy and neck lymph node metastasis on the flap was analysed. The clinical effect in the near future and longterm of submental island flap for defects repair was evaluated. RESULTS Thirty-eight submental island flap were applied for reconstruction of head and neck defects following cancer ablation between July of 1997 to December of 1999. 16 of these had preoperative radiotherapy at both donor site and receive site, and neck dissections with resection of primary lesions were simultaneously performed in 18 patients. The success rate was 89.5% (34 of 38). All repaired cases had well matched skin with facial surface and excellent texture for intraoral function. CONCLUSIONS Routine preoperative radiation does do not influence the success and healing of the flap. For tumor complete resection, appropriate cases should be chosen. We believe this flap is worthwhile in addition to the existing armamentarium of reconstruction options both facially and intraorally.
Sensory-Motor Neuropathy in Mfn2 T105M Knock-in Mice and Its Reversal by a Novel Piperine-Derived Mitofusin Activator

Jochen Weigele,Lihong Zhang,Antonietta Franco,Etienne Cartier,Gerald W. Dorn

DOI: https://doi.org/10.1124/jpet.124.002258

2024-10-19

Journal of Pharmacology and Experimental Therapeutics

Abstract:Mitochondrial dysfunction is a hallmark of many genetic neurodegenerative diseases, but therapeutic options to reverse mitochondrial dysfunction are limited. While recent studies support the possibility of improving mitochondrial fusion/fission dynamics and motility to correct mitochondrial dysfunction and resulting neurodegeneration in Charcot-Marie-Tooth disease (CMT) and other neuropathies, the clinical utility of reported compounds and relevance of preclinical models are uncertain. Here, we describe motor and sensory neuron dysfunction characteristic of clinical CMT type 2 A in a CRISPR/Casp-engineered Mfn2 Thr105Met (T105M) mutant knock-in mouse. We further demonstrate that daily oral treatment with a novel mitofusin activator derived from the natural product piperine can reverse these neurologic phenotypes. Piperine derivative 8015 promoted mitochondrial fusion and motility in Mfn2-deficient cells in a mitofusin-dependent manner and reversed mitochondrial dysfunction in cultured fibroblasts and reprogrammed motor neurons from a human CMT2A patient carrying the MFN2 T105M mutation. Like previous mitofusin activators, 8015 exhibited stereospecific functionality, but the more active stereoisomer, 8015-P2, is unique in that it has subnanomolar potency and undergoes entero-hepatic recirculation which extends its in vivo half-life. Daily administration of 8015-P2 to Mfn2 T105M knock-in mice for 6 weeks normalized neuromuscular and sensory dysfunction and corrected histological/ultrastructural neurodegeneration and neurogenic myoatrophy. These studies describe a more clinically relevant mouse model of CMT2A and an improved mitofusin activator derived from piperine. We posit that 8015-P2 and other piperine derivatives may benefit CMT2A or other neurodegenerative conditions wherein mitochondrial dysdynamism plays a contributory role. SIGNIFICANCE STATEMENT Mitochondrial dysfunction is widespread and broadly contributory in neurodegeneration, but difficult to target therapeutically. Here, we describe 8015-P2, a new small molecule mitofusin activator with ~10-fold greater potency and improved in vivo pharmacokinetics versus comparators, and demonstrate its rapid reversal of sensory and motor neuron dysfunction in an Mfn2 T105M knock-in mouse model of Charcot-Marie-Tooth disease type 2 A. These findings further support the therapeutic approach of targeting mitochondrial dysdynamism in neurodegeneration.

pharmacology & pharmacy
Oral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review

Fan-Jie Qu,Yi Zhou,Hai Wang

DOI: https://doi.org/10.2147/OTT.S430190

2023-11-15

Abstract:Malignant peritoneal mesothelioma (MPeM) is a rare and highly invasive malignant tumor with a lack of specificity in clinical manifestations, which can easily lead to misdiagnosis and missed diagnosis. Due to the difficulty of early diagnosis, most patients are already in the advanced stage when diagnosed, and the prognosis is poor. At present, there is no standard treatment strategy, and the existing treatment methods are not effective, the duration of remission is short, which cannot meet the clinical needs. Here we describe a patient with advanced MPeM, initially misdiagnosed as ovarian cancer, who responded to treatment with bevacizumab in combination with albumin-bound paclitaxel and cisplatin. In preparation for cytoreductive surgery (CRS), MPeM was confirmed by laparoscopic peritoneal nodule biopsy combined with histological and immunohistochemical results. Subsequently, due to intolerable neurotoxicity after chemotherapy, she received oral anlotinib therapy on April 25, 2022, and remained stable disease (SD) with the medication, having achieved more than 14 months of progression-free survival (PFS) as of the date of our manuscript submission. The patient's total treatment time was over 19 months. These treatments delayed tumor progression, reduced drug side effects, maintained a good quality of life, and further extended overall survival (OS). Our experience is that on the one hand, it is necessary to increase the clinician's understanding of the disease, and make full use of tissue samples and immunohistochemical staining to reduce the occurrence of misdiagnosis. On the other hand, based on preliminary evidence, we found that oral anlotinib offers a viable maintenance treatment strategy for patients with advanced mesothelioma, which needs to be further explored in future studies.
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH

Justine M Mucinski,Amadeo F Salvador,Mary P Moore,Talyia M Fordham,Jennifer M Anderson,Grace Shryack,Rory P Cunningham,Guido Lastra,Ayman H Gaballah,Alberto Diaz-Arias,Jamal A Ibdah,R Scott Rector,Elizabeth J Parks

DOI: https://doi.org/10.1016/j.jhep.2024.06.017

Abstract:Background & aims: Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common liver diseases worldwide and is characterized by multi-tissue insulin resistance. The effects of a 10-month energy restriction and exercise intervention on liver histology, anthropometrics, plasma biochemistries, and insulin sensitivity were compared to standard of care (control) to understand mechanisms that support liver health improvements. Methods: Following medical diagnosis of MASH, individuals were randomized to treatment (n = 16) or control (n = 8). Liver fat (magnetic resonance spectroscopy), 18-hour plasma biochemical measurements, and isotopically labeled hyperinsulinemic-euglycemic clamps were completed pre- and post-intervention. Body composition and cardiorespiratory fitness (VO2peak) were also measured mid-intervention. Those in the treatment group were counseled to reduce energy intake and completed supervised, high-intensity interval training (3x/week) for 10 months. Controls continued physician-directed care. Results: Treatment induced significant (p <0.05) reductions in body weight, fat mass, and liver injury, while VO2peak (p <0.05) and non-esterified fatty acid suppression (p = 0.06) were improved. Both groups exhibited reductions in total energy intake, hemoglobin A1c, hepatic insulin resistance, and liver fat (p <0.05). Compared to control, treatment induced a two-fold increase in peripheral insulin sensitivity which was significantly related to higher VO2peak and resolution of liver disease. Conclusions: Exercise and energy restriction elicited significant and clinically meaningful treatment effects on liver health, potentially driven by a redistribution of excess nutrients to skeletal muscle, thereby reducing hepatic nutrient toxicity. Clinical guidelines should emphasize the addition of aerobic exercise in lifestyle treatments for the greatest histologic benefit in individuals with advanced MASH. Impact and implications: The mechanisms that underpin histologic improvement in individuals with metabolic dysfunction-associated steatohepatitis (MASH) are not well understood. This study evaluated the relationship between liver and metabolic health, testing how changes in one may affect the other. We investigated the effects of energy restriction and exercise on the association between multi-tissue insulin sensitivity and histologic improvements in participants with biopsy-proven MASH. For the first time, these results show that an improvement in peripheral (but not hepatic) insulin sensitivity and systemic markers of muscle function (i.e. cardiorespiratory fitness) were strongly related to resolution of liver disease. Extrahepatic disposal of substrates and improved fitness levels supported histologic improvement, confirming the addition of exercise as crucial to lifestyle interventions in MASH. Clinical trial number: NCT03151798.

ON POISONS AND DISEASE AND SOME EXPERIMENTS WITH THE TOXIN OF THE BACILLUS TETANI.

Power-assisted liposuction (PAL) of multiple symmetric lipomatosis (MSL)--a longitudinal study

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

Integrated proteomic and metabolomic analyses of the mitochondrial neurodegenerative disease MELAS

A Mediterranean Diet-Oriented Intervention Rescues Impaired Blood Cell Bioenergetics in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Mitophagy modulation rescues single large-scale mitochondrial DNA deletion (SLSMD) disease symptoms in the C. elegans uaDf5 animal model.

AI-based Digital Pathology Provides Newer Insights into Lifestyle Intervention-Induced Fibrosis Regression in MASLD: an Exploratory Study.

Metabolic effects of bezafibrate in mitochondrial disease

Copyright enforcement in the digital age: a post-ACTA view on the balancing of fundamental rights

Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?

Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes

Surgical animal model of ventricular hypertrophy.

Repeated measurements and data integration to monitor and study MASLD patients experiencing weight loss

1 nJ all-fiber 108 MHz mode-locked erbium oscillator at 1.56 /spl mu/m

Repurposing of the analgesic Neurotropin for MASLD/MASH treatment

Circulating mitochondrial bioenergetic profile reflects the hepatic one and represents a non-invasive biomarker of disease severity in MASLD genetically predisposed individuals

Duodenal and jejunal diverticula causing a pneumoperitoneum.

[Evaluation for submental island flap].

Sensory-Motor Neuropathy in Mfn2 T105M Knock-in Mice and Its Reversal by a Novel Piperine-Derived Mitofusin Activator

Oral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review

Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH